Initiate a Phase 2 study in anemia of myelofibrosis
Delivered by the deadline
AI-confirmed · human review in progress Independent AI checks agreed on primary SEC or regulator evidence. Records are now being reviewed by hand, starting with those our customers order.
- Announced
- 12 Nov 2024
- Due
- 31 Dec 2024
- Delivered
- December 2024
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“The Company expects to initiate a Phase 2 study in anemia of myelofibrosis (MF) by the end of 2024”
What we found
Evidence strength A What the grades mean
The company initiated the open-label Phase 2 portion of its clinical trial for anemia of myelofibrosis in December 2024, meeting its commitment to do so by the end of 2024.
-
A Disc Medicine, Inc. 10-K filed 2025-02-27
“In December 2024, we initiated the open-label Phase 2 part of our Phase 1b/2 clinical trial to evaluate the safety, tolerability and efficacy of DISC-0974 in patients with anemia of MF.” ✓ confirmed on the page
Market reaction: the shares moved +1.6% against the S&P 500 over the three sessions around the disclosure (26 Feb 2025 to 3 Mar 2025). What this measures
Checked 1 Oct 2026.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Clinical milestone
- Indicative materiality
- Medium rules
- Action
- Initiate
- Deliverable
- Phase 2 study in anemia of myelofibrosis
- Language
- Expected (“expects”, “plans”)
- In the company’s control
- High
- Specificity
- High
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Gemini (Google), read the company's later filings and recorded the outcome with a quoted passage.
- Second check: agreesA different AI model, Claude (Anthropic), re-read the evidence without being told the outcome and reached the same answer.
Confirmed. This outcome counts towards the company's Kept Score. How verification works
Are you Disc Medicine, Inc.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2024-IRON-002179 · Corrections policy